Abatacept is a biological immune modifier that is used for the treatment of rheumatoid arthritis. Although psoriasiform drug eruption is reported as one of the cutaneous adverse effects of abatacept, the precise mechanisms are not fully understood. In this report, we describe a 65-year-old Japanese man with psoriasiform drug eruption caused by abatacept. Interestingly, immunohistochemical staining revealed that the epidermal keratinocytes in the basal layer and lower layers of the stratum spinosum were positive for pSTAT3, partially positive for pSTAT1 and negative for pSTAT6, which is similar to conventional psoriasis vulgaris. Our present study suggests that psoriasiform drug eruption caused by abatacept might develop by similar immunolog...
Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical...
OBJECTIVES: To evaluate the incidence of new cases of psoriatic arthritis (PsA) in patients with pl...
Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoi...
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10% of patients with c...
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10 % of patients with ...
Introduction Psoriasis is a T‐cell driven, chronic inflammatory skin disease. In recent literature,...
Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etane...
Background: Tumor necrosis factor alpha (TNFα) antagonists are effective in treating several immune-...
Psoriatic arthritis (PsA) is a chronic inflammatory disease of joints, tendon sheaths, and entheses ...
© 2019, Serbian Medical Society. All rights reserved. The use of tumor necrosis factor antagonists (...
We read with interest the report by de Gannes et al1 concerning psoriasis triggered by tumor necrosi...
Abstract Background The aim was to study changes in immunohistochemical expression markers of synovi...
Psoriasis is a chronic inflammatory skin disorder clinically characterized by erythematous, sharply ...
Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment...
INTRODUCTION: Tumor necrosis factor (TNF)-α inhibitors are widely used for the treatment of inflamma...
Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical...
OBJECTIVES: To evaluate the incidence of new cases of psoriatic arthritis (PsA) in patients with pl...
Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoi...
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10% of patients with c...
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10 % of patients with ...
Introduction Psoriasis is a T‐cell driven, chronic inflammatory skin disease. In recent literature,...
Tumor necrosis factor-alpha antagonists include monoclonal antibodies, infliximab, adalimumab, etane...
Background: Tumor necrosis factor alpha (TNFα) antagonists are effective in treating several immune-...
Psoriatic arthritis (PsA) is a chronic inflammatory disease of joints, tendon sheaths, and entheses ...
© 2019, Serbian Medical Society. All rights reserved. The use of tumor necrosis factor antagonists (...
We read with interest the report by de Gannes et al1 concerning psoriasis triggered by tumor necrosi...
Abstract Background The aim was to study changes in immunohistochemical expression markers of synovi...
Psoriasis is a chronic inflammatory skin disorder clinically characterized by erythematous, sharply ...
Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment...
INTRODUCTION: Tumor necrosis factor (TNF)-α inhibitors are widely used for the treatment of inflamma...
Recently, the tumor necrosis factor-α inhibitors (anti-TNF-α) have been extensively used in clinical...
OBJECTIVES: To evaluate the incidence of new cases of psoriatic arthritis (PsA) in patients with pl...
Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoi...